Evotec AG has launched its accelerated drug development service INDiGO. 

INDiGO is a proven development solution that has been successfully executed by Evotec’s recent acquisition of Aptuit for several years. The service has been proven to reduce the time and cost of pre-clinical drug development whilst delivering a high-quality data package for CTA/IND level regulatory filings. 

INDiGO services range from API manufacture, formulation development, clinical supply, safety assessment, DMPK, bioanalysis and biomarkers, to regulatory submission documents preparation.

Evotec’s partners benefit from a single, integrated provider for all required functions and capabilities coupled with best-in-class project management and seasoned scientific leadership.

“Evotec’s INDiGO delivers to our partners a truly integrated approach to accelerate development of their drug candidates to regulatory submission in the most time- and cost-efficient manner,” said Mario Polywka, chief operating officer, Evotec. “Our track record and expertise in combing the appropriate scientific knowledge with the right technical processes and project management ensures on time and budget delivery of clinic ready candidates. INDiGO allows our customers to seamlessly transition from candidate selection into the regulatory space and to patients efficiently and quickly.” 

Roberto Dorigatti, senior vice president, integrated development programs, said, “Our INDiGO is a truly integrated drug development solution. It is unique in the industry and has a proven track record of success in dramatically reducing (by more than 50%) time and costs during the IND-enabling phase of development and never compromising quality and scientific integrity. Our experienced team understands drug development and not only executes projects but proactively contributes to the science and strategy to expedite new medicines to the market.”